Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2012 Financial Results
Date:3/11/2013

in research and development expenses related to the Zerenex clinical program.  The net loss for the fourth quarter ended December 31, 2012, included $0.5 million of non-cash compensation expense related to equity incentive grants.

The net loss for the year ended December 31, 2012, was $22.7 million, or $0.32 per share, compared to a net loss of $28.1 million, or $0.42 per share, for the year ended December 31, 2011, representing a decrease in net loss of $5.4 million.  The change in net loss in the year ended December 31, 2012, as compared to 2011, was primarily attributable to an $8.9 million decrease in research and development expenses due to the cessation of the development of KRX-0401 (perifosine) in May 2012, partially offset by a $2.5 million increase in research and development expenses related to the Zerenex clinical program.  The net loss for the year ended December 31, 2011, included license revenue of $5.0 million related to a milestone payment from JT and Torii for their commencement, in April 2011, of a Phase 3 clinical program in Japan.  The net loss for the year ended December 31, 2012, included a non-cash extraordinary gain of $2.6 million related to a write-off of the contingent equity rights liability following the termination of the license agreement for KRX-0401 in May 2012 and $2.2 million of non-cash compensation expense related to equity incentive grants. 

Ron Bentsur , the Company's Chief Executive Officer, commented, "In January, we reached a major milestone with the announcement of successful top-line results from the long-term Phase 3 study of Zerenex.  Following that announcement, we solidified our balance sheet with a substantial capital raise, allowing us to focus on the next key milestones for the Company, specifically, our pending U.S. New Drug Application and European Marketing Authorization Application filings and a potential launch for Zerenex in the middl
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Fourth Quarter and Year-End 2012 Financial Results
2. Keryx Biopharmaceuticals to Present at the Citigroup 2013 Global Healthcare Conference
3. Keryx Biopharmaceuticals Announces Pricing of Public Offering of Common Stock
4. Keryx Biopharmaceuticals Announces $55 Million Proposed Public Offering of Common Stock
5. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Third Quarter 2012 Financial Results
6. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Second Quarter 2012 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
8. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
9. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
10. Par Pharmaceutical Announces Quarterly Conference Call
11. HeartWare International, Inc. Announces Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... YORK , May 28, 2015 /PRNewswire/ ... developing new drugs and tests, and this ... the instruments that can assist them. This according ... publisher. Kalorama Information said instruments such as mass ... assist in the identification of drug targets ...
(Date:5/28/2015)... , May 28, 2015  IRIDEX Corporation (NASDAQ: IRIX ... Officer James H. Mackaness is scheduled to present ... at 9:00 am PT in Los Angeles ... may be accessed on the Event Calendar of the Investors ... of the webcast will be available shortly after the conclusion ...
(Date:5/28/2015)... , May 28, 2015 ... the addition of the "United States Medical ... to their offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... in the United States ... Medical device manufacturers across the ...
Breaking Medicine Technology:Report: Proteomics Research Market Reaches $1.6 Billion 2Report: Proteomics Research Market Reaches $1.6 Billion 3United States Medical Adhesives Market Forecast and Opportunities, 2020 - New Medical Innovations with 3M, Henkel Adhesive Research, Ethicon and Cyberbond Dominating 2United States Medical Adhesives Market Forecast and Opportunities, 2020 - New Medical Innovations with 3M, Henkel Adhesive Research, Ethicon and Cyberbond Dominating 3
... -- The,first of two stages of the ... Kamada's Alpha-1 Antitrypsin (AAT) liquid drug,candidate for ... the treatment of patients suffering from AAT,deficiency. ... profiles,and patient tolerability, leading the way to ...
... WIRE)--Jun 1, 2007 - Arrowhead Research,Corporation (Nasdaq:ARWR) ... been published in the 2007 American Society ... The data are from,an ongoing Phase I ... and pharmacokinetics of its lead anti-cancer drug,candidate, ...
Cached Medicine Technology:PARI and Kamada Announce Positive Intermediate Phase I Results for,Inhaled Alpha-1 Antitrypsin 2PARI and Kamada Announce Positive Intermediate Phase I Results for,Inhaled Alpha-1 Antitrypsin 3Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data from,Human Clinical Trials for New Cancer Drug 2Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data from,Human Clinical Trials for New Cancer Drug 3
(Date:5/29/2015)... New York, New York (PRWEB) May 29, 2015 ... and distributor of patented products, announces that it has ... Chat Room, a technology patent that aims to let ... various industry experts in real time. , "This is ... Expert Chat Room " said Scott J. Cooper, CEO ...
(Date:5/29/2015)... 2015 The print component of “Skin ... of approximately 250,000 and an estimated readership of 750,000. ... social media strategy, and across a network of top ... version of the campaign, click here. , ... Inside, the actress, model and producer details her skin ...
(Date:5/29/2015)... May 29, 2015 The campaign focuses ... as a number of specific concerns within, including the ... and mental health in the workplace. We are encouraged ... The campaign also brings special focus to people living ... speak up and seek help from healthcare professionals and ...
(Date:5/29/2015)... La Mirada, Ca (PRWEB) May 29, 2015 ... services, including pain consultations with specialists, physical therapy, ... who are experiencing mid back and/or lower back ... offering lumbar epidural injections for herniated discs, disc ... spine pain . , Healthpointe’s team of ...
(Date:5/29/2015)... The Global Allopurinol Industry Report ... the current state of the Allopurinol industry.With 147 ... on the state of the industry and is ... companies and individuals interested in the market. The ... including definitions, classifications, applications and industry chain structure. ...
Breaking Medicine News(10 mins):Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 2Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 3Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 4Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 5Health News:Mediaplanet Brings Activism to Those Living with Mental Illness in Bew “Mental Health Awareness” Campaign 2Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 2Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 3Health News:Allopurinol Industry (Global, China) 2015 Research Analysis and 2020 Forecasts 2
... Discovery shows how a group of molecules pulls certain ... a finding that could,help development of new cancer drugs, ... St.,Jude Children,s Research Hospital scientists offers new insights into ... could lead to new,cancer treatments., The researchers identified ...
... - Neurochem,(International) Limited (Neurochem), a wholly-owned subsidiary of ... that the Company has received an,acknowledgement from the ... response to the July 2007 approvable letter for ... the treatment of,Amyloid A (AA) amyloidosis is a ...
... Belinda Tsao-Nivaggioli,Chief Executive Officer of Avicena Group, Inc. ... featured in an exclusive interview,with http://www.wallst.net ... The interview,will be posted on http://www.wallst.net ... The interview will cover topics including Avicena Group,s ...
... University of Pennsylvania School of Medicine and other ... care providers can better their chances of identifying ... the way they ask patients questions., In a ... Internal Medicine, researchers found a number of communication ...
... malignancies at bay, research shows , , THURSDAY, Dec. 6 ... the key to cancer prevention, since new research shows ... reduce the risk of esophageal and bladder cancers. , ... Thursday at the American Association for Cancer Research,s Sixth ...
... Delays This Holiday Season May Lead to Kissing in ... flying during,the holidays normally conjures up images of screaming ... keep bumping,into your elbow with the drink cart. But ... Worst Airports to Make a Connection" study, which was,announced ...
Cached Medicine News:Health News:St. Jude Finds Mechanism for Faulty Protein Disposal 2Health News:Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review 2Health News:Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review 3Health News:WallSt.net Announces Upcoming Interview With CEO of Avicena Group 2Health News:Finding the right words: Provider-patient discussions can help domestic violence victims speak up 2Health News:Blackberries, Broccoli Sprouts Battle Cancer 2Health News:Blackberries, Broccoli Sprouts Battle Cancer 3Health News:Blackberries, Broccoli Sprouts Battle Cancer 4Health News:Philly International Airport Tops 'AXE's Best and Worst Airports to Make a Connection' 2Health News:Philly International Airport Tops 'AXE's Best and Worst Airports to Make a Connection' 3Health News:Philly International Airport Tops 'AXE's Best and Worst Airports to Make a Connection' 4Health News:Philly International Airport Tops 'AXE's Best and Worst Airports to Make a Connection' 5
Sterile squares of smooth foil for repair of the floor of the orbit and other plastic surgery. Available in large size....
Clear Base Stand Magnifiers are ideal for any visual task that requires high magnification....
Bausch & Lomb magnifiers incorporates precision optics and patented ergonomic designs for increased clarity and comfort during use....
Ultra Thin Sheet. Medpor Sheets are commonly used for orbital floor reconstruction and other craniofacial applications....
Medicine Products: